Sleep microstructure and neurodegeneration as measured by [123I]?-CIT SPECT in treated patients with Parkinson?s disease

Happe, Svenja; Anderer, P.; Pirker, Walter; Klösch, Gerhard; Gruber, Georg; Saletu, B.; Zeitlhofer, J.

doi:10.1007/s00415-004-0564-3

Cited by 21 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with our and other groups' prior findings (Emser et al, 1988;Christensen et al, 2014a;Latreille et al, 2015), but contradicts those of other studies (Happe et al, 2004). According to Braak et al (2003), the neurodegenarative progress in PD shows a progressive ascending course starting from the brain stem and spreading to additional brain structures.…”

Section: Discussionsupporting

confidence: 36%

Sleep spindle alterations in patients with Parkinson's disease

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 36%

Sleep spindle alterations in patients with Parkinson's disease

et al. 2015

View full text Add to dashboard Cite

“…There was a trend for more sleep fragmentation in patients without motor fluctuations and on lower dose of levodopa. Dopaminergic agents can influence sleep and it is recognized that this influence is variable and probably works on an individual basis [20][21][22]. Obstructive sleep apnea without severe oxygen desaturation was common in our series.…”

Section: Discussionmentioning

confidence: 85%

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease

et al. 2007

View full text Add to dashboard Cite

Insomnia, sleep fragmentation and excessive daytime sleepiness are common in Parkinson's disease (PD) and may contribute to the reduction of cognition and alertness in those patients. Melatonin has been shown to improve sleep in several conditions. In experimental models of PD, melatonin can ameliorate motor symptoms. To evaluate the effect of melatonin on sleep and motor dysfuntion in PD, we studied 18 patients (Hoehn & Yahr I to III) from a PD clinic. Prior to treatment, motor dysfunction was assessed by UPDRS II, III and IV. Subjective sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence by the Epworth Sleepiness Scale (ESS). Full polysomnography (PSG) was performed in all subjects. Patients were then randomized to receive melatonin (3mg) or placebo one hour before bedtime for four weeks. All measures were repeated at the end of treatment. On initial assessment, 14 patients (70%) showed poor quality sleep (PSQI > 6) and eight (40%) excessive daytime sleepiness (ESS > 10). Increased sleep latency (50%), REM sleep without atonia (66%), and reduced sleep efficiency (72%) were found on PSG. Eight patients had an apnea/ hipopnea index greater than 15 but no severe oxygen desaturation was observed. Sleep fragmentation tended to be more severe in patients on lower doses of levodopa (p = 0.07). Although melatonin significantly improved subjective quality of sleep (p = 0.03) as evaluated by the PSQI index, PSG abnormalities were not changed. Motor dysfunction was not improved by the use of melatonin. Undetected differences in motor scores and PSG findings may have been due to a small sample size and a type II error.

show abstract

“…(Brunner et al., ; Diederich, Vaillant, Leischen et al., ; Happe et al., ; Latreille et al., ; Wailke et al., )…”

Section: Resultsunclassified

An overview of sleep and circadian dysfunction in Parkinson's disease

Mantovani

Smith

Gordon

et al. 2018

Journal of Sleep Research

View full text Add to dashboard Cite

Sleep and circadian alterations are amongst the very first symptoms experienced in Parkinson's disease, and sleep alterations are present in the majority of patients with overt clinical manifestation of Parkinson's disease. However, the magnitude of sleep and circadian dysfunction in Parkinson's disease, and its influence on the pathophysiology of Parkinson's disease remains often unclear and a matter of debate. In particular, the confounding influences of dopaminergic therapy on sleep and circadian dysfunction are a major challenge, and need to be more carefully addressed in clinical studies. The scope of this narrative review is to summarise the current knowledge around both sleep and circadian alterations in Parkinson's disease. We provide an overview on the frequency of excessive daytime sleepiness, insomnia, restless legs, obstructive apnea and nocturia in Parkinson's disease, as well as addressing sleep structure, rapid eye movement sleep behaviour disorder and circadian features in Parkinson's disease. Sleep and circadian disorders have been linked to pathological conditions that are often co-morbid in Parkinson's disease, including cognitive decline, memory impairment and neurodegeneration. Therefore, targeting sleep and circadian alterations could be one of the earliest and most promising opportunities to slow disease progression. We hope that this review will contribute to advance the discussion and inform new research efforts to progress our knowledge in this field.

show abstract

Sleep microstructure and neurodegeneration as measured by [123I]?-CIT SPECT in treated patients with Parkinson?s disease

Abstract: K-complexes and sleep spindles are not reduced and do not seem to be related to the degree of dopaminergic degeneration in treated PD patients.

Cited by 21 publications

References 32 publications

Sleep spindle alterations in patients with Parkinson's disease

Sleep spindle alterations in patients with Parkinson's disease

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease

An overview of sleep and circadian dysfunction in Parkinson's disease

Contact Info

Product

Resources

About